Fracture risk assessment based on FRAX scores and Polish guidelines in patients with newly diagnosed osteopaenia
, 2, 1, 1
Abstract
Introduction: A densitometric diagnosis of osteoporosis qualifies patients to a diagnostic-therapeutic process, but densitometric evaluation may not be sufficient for osteopaenic patients. Therefore, it is essential to assess osteoporosis risk factors, fracture history, and 10-year fracture risk, and classify patients into low-, medium-, high-, or very high-risk categories. In our study, we aimed to assess the risk of fractures in patients with newly diagnosed osteopaenia and determine the percentage of patients at high and very high risk of fracture.
Material and methods: The study included 89 postmenopausal women with newly diagnosed osteopaenia as determined by a T-score of the femoral neck and/or lumbar spine from dual-energy X-ray absorptiometry (DXA) scans between –1.0 and –2.5 standard deviations (SD). Demographic data and laboratory tests were collected. Additionally, based on the Fracture Risk Assessment Tool (FRAX-PL) calculator including bone mineral density (BMD), 10-year fracture risk was calculated for major osteoporotic fractures (FRAX MOF) and hip fractures (FRAX HF). Each patient was then classified into particular risk groups based on FRAX and modified fracture risk assessment criteria. Results: Our study found the most common risk factors to be glucocorticoid intake (47.19%), parental hip fracture (46.07%), and smoking (39.33%). In the general population, 56.6% of subjects had at least one fracture in adulthood. The FRAX calculator showed that 39.33% of the patients had a very high risk of HF and 34.83% had a very high risk of major osteoporotic fractures (MOF). A high fracture risk for hip fractures (HF) and MOF was noted in 11.24% and 40.45% of the patients, whereas a medium and low risk of MOF was seen in 17.98% and 6.74%, respectively. Significantly more subjects (53.93%) had been classified as being at very high risk of fracture, based on the expanded criteria than on the basis of FRAX alone. Of these, 48.31% met the criteria of FRAX > 15% for MOF or > 4.5% for HF, and 7.87% had multiple (≥ 2) major fractures. Women aged 70-75 years were at the highest risk of fracture.
Conclusions: Our findings highlight the importance of categorising fracture risk in osteopaenic patients, and show that the number of patients at very high fracture risk increases when the expanded criteria from the latest Polish guidelines are applied.
Keywords: fracture riskFRAXvery high risk for fracturesguidelinesosteopaenia
References
- Trajanoska K, Schoufour J, Jonge Ede, et al. Fracture incidence and secular trends between 1989 and 2013 in a population based cohort: The Rotterdam Study. Bone. 2018; 114: 116–124.
- Kanis JA, Melton LJ, Christiansen C, et al. The diagnosis of osteoporosis. J Bone Miner Res. 1994; 9(8): 1137–1141.
- Reid IR, McClung MR. Osteopenia: a key target for fracture prevention. Lancet Diabetes Endocrinol. 2024; 12(11): 856–864.
- Camacho P, Petak S, Binkley N, et al. American Association of Clinical Endocrinologists/American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis—2020 Update. Endocr Pract. 2020; 26: 1–46.
- Al-Saleh Y, Al-Daghri NM, Sabico S, et al. Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis (ESCEO) and the Committees of Scientific Advisors and National Societies of the International Osteoporosis Foundation (IOF), Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis (ESCEO) and the Committees of Scientific Advisors and National Societies of the International Osteoporosis Foundation (IOF), Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the Committees of Scientific Advisors and National Societies of the International Osteoporosis Foundation (IOF), Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the Committees of Scientific Advisors and National Societies of the International Osteoporosis Foundation (IOF), Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis (ESCEO) and the Committees of Scientific Advisors and National Societies of the International Osteoporosis Foundation (IOF), Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the Committee of Scientific Advisors of the International Osteoporosis Foundation (IOF), European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2008; 19(4): 399–428.
- Głuszko P, Sewerynek E, Misiorowski W, et al. Guidelines for the diagnosis and management of osteoporosis in Poland. Update 2022. Endokrynol Pol. 2023; 74(1): 5–15.
- Kanis JA, Johnell O, Oden A, et al. FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int. 2008; 19(4): 385–397.
- Bouxsein ML, Eastell R, Lui LY, et al. FNIH Bone Quality Project. Change in Bone Density and Reduction in Fracture Risk: A Meta-Regression of Published Trials. J Bone Miner Res. 2019; 34(4): 632–642.
- Głuszko P. Osteoporoza — postępy 2023/2024. Med Prakt. 2024; 4: 71–77.
- Johansson H, Siggeirsdóttir K, Harvey NC, et al. Imminent risk of fracture after fracture. Osteoporos Int. 2017; 28(3): 775–780.
- Kanis JA, Johansson H, Harvey NC, et al. Correspondence in response to OSIN-D-18-00831 quantifying imminent risk. Osteoporos Int. 2019; 30(2): 525–526.
- Leslie WD, Lix LM, Johansson H, et al. Spine-hip discordance and fracture risk assessment: a physician-friendly FRAX enhancement. Osteoporos Int. 2011; 22(3): 839–847.
- Kanis JA, Johansson H, Oden A, et al. Guidance for the adjustment of FRAX according to the dose of glucocorticoids. Osteoporos Int. 2011; 22(3): 809–816.
- Watts NB, Manson JE. Osteoporosis and Fracture Risk Evaluation and Management: Shared Decision Making in Clinical Practice. JAMA. 2017; 317(3): 253–254.
- Shepstone L, Lenaghan E, Cooper C, et al. SCOOP Study Team. A pragmatic randomised controlled trial of the effectiveness and cost-effectiveness of screening older women for the prevention of fractures: rationale, design and methods for the SCOOP study. Osteoporos Int. 2012; 23(10): 2507–2515.
- FRAX. Kalkulator ryzyka złamania. https://frax.shef.ac.uk/FRAX/tool.aspx?lang=po.
- Baek YH, Cho SW, Jeong HE, et al. 10-Year Fracture Risk in Postmenopausal Women with Osteopenia and Osteoporosis in South Korea. Endocrinol Metab (Seoul). 2021; 36(6): 1178–1188.
- Siris ES, Miller PD, Barrett-Connor E, et al. Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment. JAMA. 2001; 286(22): 2815–2822.
- Mai HaT, Tran TS, Ho-Le TP, et al. Two-Thirds of All Fractures Are Not Attributable to Osteoporosis and Advancing Age: Implications for Fracture Prevention. J Clin Endocrinol Metab. 2019; 104(8): 3514–3520.
- Kanis JA, McCloskey EV, Harvey NC, et al. The need to distinguish intervention thresholds and diagnostic thresholds in the management of osteoporosis. Osteoporos Int. 2023; 34(1): 1–9.
- Tomasevic-Todorovic S, Vazic A, Issaka A, et al. Comparative assessment of fracture risk among osteoporosis and osteopenia patients: a cross-sectional study. Open Access Rheumatol. 2018; 10: 61–66.
- Walker MD, Shane E, Walker MD, et al. Postmenopausal Osteoporosis. N Engl J Med. 2023; 389(21): 1979–1991.
- Ensrud K, Crandall C. Osteoporosis. Ann Intern Med. 2024; 177(1): ITC1–ITC16.
- LeBoff MS, Greenspan SL, Insogna KL, et al. The clinician's guide to prevention and treatment of osteoporosis. Osteoporos Int. 2022; 33(10): 2049–2102.
- Leslie WD, Morin SN, Lix LM, et al. Comparison of treatment strategies and thresholds for optimizing fracture prevention in Canada: a simulation analysis. Arch Osteoporos. 2019; 15(1): 4.
- Reid IR, Horne AM, Mihov B, et al. Anti-fracture efficacy of zoledronate in subgroups of osteopenic postmenopausal women: secondary analysis of a randomized controlled trial. J Intern Med. 2019; 286(2): 221–229.
- Quandt SA, Thompson DE, Schneider DL, et al. Fracture Intervention Trial Research Group. Effect of alendronate on vertebral fracture risk in women with bone mineral density T scores of-1.6 to -2.5 at the femoral neck: the Fracture Intervention Trial. Mayo Clin Proc. 2005; 80(3): 343–349.
- Siris ES, Simon JA, Barton IP, et al. Effects of risedronate on fracture risk in postmenopausal women with osteopenia. Osteoporos Int. 2008; 19(5): 681–686.
- Reid IR, Horne AM, Mihov B, et al. Fracture Prevention with Zoledronate in Older Women with Osteopenia. N Engl J Med. 2018; 379(25): 2407–2416.
- Reid IR, Horne AM, Mihov B, et al. Duration of fracture prevention after zoledronate treatment in women with osteopenia: observational follow-up of a 6-year randomised controlled trial to 10 years. Lancet Diabetes Endocrinol. 2024; 12(4): 247–256.
- Lindsay R, Hart DM, Forrest C, et al. Prevention of spinal osteoporosis in oophorectomised women. Lancet. 1980; 2(8205): 1151–1154.
- Cauley JA, Robbins J, Chen Z, et al. Women's Health Initiative Investigators. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. JAMA. 2003; 290(13): 1729–1738.
- McClung MR, Boonen S, Törring O, et al. Effect of denosumab treatment on the risk of fractures in subgroups of women with postmenopausal osteoporosis. J Bone Miner Res. 2012; 27(1): 211–218.
- Gnant M, Pfeiler G, Dubsky PC, et al. Austrian Breast and Colorectal Cancer Study Group. Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2015; 386(9992): 433–443.
